JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. 🌐 JAMAOncology.comhttps://bsky.app/profile/jamaoncology.comhttps://bsky.app/profile/jamaoncology.com/post/3mliw7z2gm723Nearly half of older adults with metastatic #LungCancer did not receive systemic therapy, and treatment rates changed minimally from 2006 to 2021. ja.ma/42nVC3G10 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mliw7z2gm723https://bsky.app/profile/jamaoncology.com/post/3ml4dveb7sz2rAmong US cancer survivors, rates of lifestyle advice from health professionals remained stable 2011–2020, but advice was consistently associated with higher engagement in recommended behaviors. ja.ma/4cMrBAy05 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3ml4dveb7sz2rhttps://bsky.app/profile/jamaoncology.com/post/3ml4ak2jqf52cIn advanced nonsquamous #NonSmallCellLungCancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles. ja.ma/4vZBDFQ05 May 2026 13:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3ml4ak2jqf52chttps://bsky.app/profile/jamaoncology.com/post/3mkztgg7yuz2wMaintenance rucaparib provided >5-year progression-free survival for 16% of patients with #PancreaticCancer and BRCA/PALB2 variants; resistance mechanisms were detected in half of those with disease progression. ja.ma/4d0xt8304 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkztgg7yuz2whttps://bsky.app/profile/jamaoncology.com/post/3mkxjo3perj2wA 60-year-old woman presented with progressive right lower extremity radiculopathy and numbness, a pigmented skin lesion on the right side of the chest, and right ankle jerk reflex. What is your diagnosis? ja.ma/3QLtyob03 May 2026 16:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkxjo3perj2whttps://bsky.app/profile/jamaoncology.com/post/3mkxcxjak6a22Adult T-cell leukemia/lymphoma incidence among non-Hispanic Caribbean-born US residents approaches endemic region levels, with early-life human T-cell leukemia virus type 1 infection via maternal transmission identified as an actionable prevention target. ja.ma/42G9Xs703 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkxcxjak6a22https://bsky.app/profile/jamaoncology.com/post/3mkuz75j7tt2xLocal salvage therapies alone for #ProstateCancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. ja.ma/4djZetv02 May 2026 16:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkuz75j7tt2xhttps://bsky.app/profile/jamaoncology.com/post/3mkusil26m423In advanced nonsquamous #NonSmallCellLungCancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles. ja.ma/4eiSCwz02 May 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkusil26m423https://bsky.app/profile/jamaoncology.com/post/3mkuigq6qgg2r📄 This JAMA Oncology Patient Page describes different types of common mouth problems during #cancer treatment and how to care for them. ja.ma/48Cu7qB02 May 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkuigq6qgg2rhttps://bsky.app/profile/jamaoncology.com/post/3mkft2e5tey2kThe AQUILA trial criteria classified more high-risk smoldering multiple myeloma but most had lower progression risk while the 2/20/20 model more accurately identified those likely to benefit from early treatment. ja.ma/4u8CgLB26 Apr 2026 15:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkft2e5tey2khttps://bsky.app/profile/jamaoncology.com/post/3mkffn6qwir2cOpen-source #AI models for #LungCancer EGFR mutation prediction showed high accuracy overall but reduced performance in Asian patients and pleural samples, indicating the need for broader validation. ja.ma/4uatWei26 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkffn6qwir2chttps://bsky.app/profile/jamaoncology.com/post/3mkcv6bhlx422Fifteen-year follow-up of the SWOG S0016 trial demonstrates that 42% of patients with advanced-stage #FollicularLymphoma treated with CHOP-based chemoimmunotherapy achieve functional cure. ja.ma/4u652MT25 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkcv6bhlx422https://bsky.app/profile/jamaoncology.com/post/3mkaor7smxr2wFrom 2018 to 2023, use of minimally invasive surgery (MIS) for stage I #OvarianCancer increased, but MIS was linked to higher intraoperative capsule rupture rates and lower overall survival when rupture occurred. ja.ma/4cN6FIh24 Apr 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkaor7smxr2whttps://bsky.app/profile/jamaoncology.com/post/3mkaepdkewt2k💬Editorial: SONIA demonstrates that reserving #CDK46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #BreastCancer, supporting individualized sequencing and shared decision-making. ja.ma/4dZWna124 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mkaepdkewt2khttps://bsky.app/profile/jamaoncology.com/post/3mk6mbcnoyz22The AQUILA trial criteria classified more high-risk smoldering multiple myeloma but most had lower progression risk while the 2/20/20 model more accurately identified those likely to benefit from early treatment. ja.ma/3OXZbdy23 Apr 2026 18:10 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mk6mbcnoyz22https://bsky.app/profile/jamaoncology.com/post/3mk5uagslhh2xIn recurrent or metastatic #NasopharyngealCancer, tislelizumab plus chemotherapy led to longer overall survival and durable progression-free survival compared with placebo plus chemotherapy. ja.ma/3OWRww223 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mk5uagslhh2xhttps://bsky.app/profile/jamaoncology.com/post/3mjwctnrmfq23In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications. AJWLight LondonProstate1 TaimurShah ja.ma/3OSJhkF20 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mjwctnrmfq23https://bsky.app/profile/jamaoncology.com/post/3mjrlzyzy4s26Increasing young-onset #ColorectalCancer mortality in the US was concentrated in lower educational groups, highlighting widening disparities by socioeconomic status. ja.ma/4sGvAmM18 Apr 2026 14:01 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mjrlzyzy4s26https://bsky.app/profile/jamaoncology.com/post/3mjp7gy23hc2fEarly 18F-fluorodeoxyglucose positron emission tomography after 2 weeks of therapy identified patients w/ metastatic #BreastCancer at higher risk for poor outcomes before standard CT, supporting its use to enhance prognostication and management decisions. ja.ma/4sBfx9L17 Apr 2026 15:10 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mjp7gy23hc2fhttps://bsky.app/profile/jamaoncology.com/post/3mjoy5ilpyx2pBireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #BreastCancer after endocrine progression. ja.ma/47ByFgd17 Apr 2026 13:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mjoy5ilpyx2phttps://bsky.app/profile/jamaoncology.com/post/3mjms2e3ilr2dPatients with #Cancer aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often received palliative care later in the disease course compared to the general cancer population. ja.ma/4cMhZ8K16 Apr 2026 16:05 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mjms2e3ilr2dhttps://bsky.app/profile/jamaoncology.com/post/3mja42keyix2wGenomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. ja.ma/4mkDsZH https://ja.ma/4mkDsZH11 Apr 2026 15:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mja42keyix2whttps://bsky.app/profile/jamaoncology.com/post/3mj5jnxkohu22After discontinuing pembrolizumab among patients with advanced #NonSmallCellLungCancer survival outcomes were high and subsequent immunotherapy use was rare. ja.ma/4dYbj8L10 Apr 2026 14:25 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mj5jnxkohu22https://bsky.app/profile/jamaoncology.com/post/3mj3a5mdugc2xThe 9-valent #HPV vaccine was linked to reduced risk of #HPVRelatedCancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. ja.ma/41km0ef09 Apr 2026 16:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mj3a5mdugc2xhttps://bsky.app/profile/jamaoncology.com/post/3mj2sqhlgsu22Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #BreastCancer after endocrine progression. ja.ma/4bFvNBu09 Apr 2026 12:30 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mj2sqhlgsu22https://bsky.app/profile/jamaoncology.com/post/3miofgs3gjw2rClonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #BreastCancer. ja.ma/4mcHq6r04 Apr 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3miofgs3gjw2rhttps://bsky.app/profile/jamaoncology.com/post/3miluxuyjib2xPretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #ProstateCancer ja.ma/4c30MGm03 Apr 2026 14:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3miluxuyjib2xhttps://bsky.app/profile/jamaoncology.com/post/3milkvzasre2uThe addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. ja.ma/4scbAbA03 Apr 2026 11:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3milkvzasre2uhttps://bsky.app/profile/jamaoncology.com/post/3mij5senhkt2yLow-dose aspirin in older adults was not associated with lower #Cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period. ja.ma/415gY5802 Apr 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3mij5senhkt2yhttps://bsky.app/profile/jamaoncology.com/post/3migndhv5al24Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. ja.ma/415XcXa01 Apr 2026 12:00 +0000at://did:plc:rj6cle4uinetvpabgdddcemo/app.bsky.feed.post/3migndhv5al24